Clinical Trial: Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization

Brief Summary: The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary

Detailed Summary: Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months
Sponsor: Instituto de Olhos de Goiania

Current Primary Outcome: Efficacy [ Time Frame: To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up. ]

8 patients with subfoveal PM-CNV, were treated with of 2 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. AII were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 1 year.


Original Primary Outcome: Same as current

Current Secondary Outcome: Safety and Tolerability [ Time Frame: To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up. ]

8 patients with subfoveal PM-CNV, were treated with of 2 mg ( 0.05mL) RII. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed.


Original Secondary Outcome: Same as current

Information By: Instituto de Olhos de Goiania

Dates:
Date Received: December 31, 2013
Date Started: October 2013
Date Completion: November 2014
Last Updated: January 9, 2014
Last Verified: January 2014